Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. - Wikidata - awgldk - TriplyDB

Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

http://www.wikidata.org/entity/Q44447834

about

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic.Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates Allogeneic hematopoietic cell transplantation in septuagenarians Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done?Cardiovascular Complications of Hematopoietic Stem Cell Transplantation.Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged ≥70 Years Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.Allogeneic hematopoietic cell transplantation in patients ⩾70 years: which patients may benefit?Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.Acute myeloid leukemia and myelodysplastic syndromes in older adults.Stopping higher-risk myelodysplastic syndrome in its tracks.Reduced-intensity conditioned allogeneic SCT in adults with AML.Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.The Role of Age in Neurocognitive Functioning among Adult Allogeneic Hematopoietic Cell Transplant Recipients.Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.Aging: Treating the Older Patient.Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies.Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged ⩾60.Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment?Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.AFT survival model to capture the rate of aging and age-specific mortality trajectories among first-allogeneic hematopoietic stem cells transplant patients.

P2860

Q24195048-3B769024-6794-4D46-8C19-4789E5FDA4F7 Q33566684-2CA1C142-5177-484E-A9C9-FFA3268A50C1 Q33574209-00436E1B-905A-4B73-987A-F804CBECEEC0 Q34022803-EBE03F37-4005-4989-8C25-59C9ADD9D42F Q34514273-579010E4-3561-4918-9DC5-187EFB143B76 Q35766718-54F47158-7DE0-4A02-A11C-4EF700A07F41 Q35843555-4A539307-1805-4A72-A979-31900A5A6500 Q36615092-146ABCF5-F497-43CC-BCF1-6BFF925117B4 Q36623075-07F31FBC-D6C3-43AA-B132-E7DB63E3A372 Q37079011-25E5DE72-4934-442A-BAA9-63786DD11DC1 Q37270993-AEA4597B-FAC6-4C54-8F22-5396B6A49FEB Q38197075-0668F274-E321-46C5-920F-D48433ECB2C2 Q38234863-E8365C97-AC66-4F0B-8B58-491871E245AB Q38248180-EECE1526-8CCC-4F4D-ACBB-4EC547361DEF Q38366632-C705F247-A4C0-426B-9218-4BBBAACF62EC Q38488058-54D18E0B-5B09-47B7-971C-7A02F929AFFA Q38629963-1204F248-1AB7-451B-ADD4-66C78FE51D6B Q39002065-4DC19336-25E0-415C-B0CC-EC3B092946AE Q39013605-8B5E89A8-7F03-442E-ABC7-1F29C69B1CB3 Q40494657-45A6DCA8-A70F-4ECA-8B64-BF4EB71CFBC3 Q41564676-70D141A2-DD56-4336-A1A5-0B4056D5776A Q46389618-CD1223B3-7F91-492D-97E3-111AB693B51D Q47869630-9E305DF2-86ED-4092-80B8-FAD967D18F59 Q48568744-FF36EB53-E79B-4785-B601-856E3D3A5774 Q51766127-6B658173-4455-4C37-9D97-C9C15D8F5899

P2860

Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

http://www.wikidata.org/entity/Q44447834

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Outcomes in patients age 70 or ...... for hematologic malignancies.

@en

Outcomes in patients age 70 or ...... for hematologic malignancies.

@nl

type

label

Outcomes in patients age 70 or ...... for hematologic malignancies.

@en

Outcomes in patients age 70 or ...... for hematologic malignancies.

@nl

prefLabel

Outcomes in patients age 70 or ...... for hematologic malignancies.

@en

Outcomes in patients age 70 or ...... for hematologic malignancies.

@nl

P1433

Q44447834-0C173CCE-19C7-4F16-A7E5-3EBF14E860D1

P1476

Q44447834-81A7F813-8FBD-404E-8A5E-11C11B8E9B15

P2093

Q44447834-0088854C-46E4-41D1-AFDA-F29E0D020EF2

Q44447834-0CE56782-0B06-4CC4-980A-23C55EDDFF43

Q44447834-1F39DDD3-C5F6-473B-B705-0336A1A6840B

Q44447834-3042D457-2808-4CEE-8E11-3DDF0AD03FFC

Q44447834-45CB8F98-6B1F-444D-8095-0AE237245537

Q44447834-4D5BCFAF-8EFC-4314-94AC-C1745FC75158

Q44447834-8155A6A0-BB55-48C9-9F0C-855D679EE8B3

Q44447834-88477546-707B-4641-BE09-A90FC1A8B130

Q44447834-9E899BC4-3E15-4A52-A46B-668CC5406704

Q44447834-CF811CE5-D522-4E7D-B9DC-A29A5337DEAB

P304

Q44447834-C1049053-9B4C-4BAD-91E2-7B5B10A56558

P31

Q44447834-E910376F-8F72-4E92-AFA6-E77827290152

P356

Q44447834-1F2E7B43-A940-4872-B309-8E05230E1DCA

P433

Q44447834-AB521ACD-B13F-472B-A18A-0D03F420399D

P478

Q44447834-F060643B-CD16-4D03-838D-38104B712369

P577

Q44447834-E4C5FAC5-591C-4130-86D5-73332B3DF0FE

P5875

Q44447834-C8848CDF-F84A-46E3-B288-56EAF045FC75

P698

Q44447834-A46E5724-C5F9-4E1E-BABB-10D85FB3B378

P356

J.BBMT.2013.06.008

P1433

Biology of Blood and Marrow Transplantation

P1476

Outcomes in patients age 70 or ...... for hematologic malignancies.

@en

P2093

Andrew M Brunner

http://www.w3.org/2001/XMLSchema#string

Bimalangshu R Dey

http://www.w3.org/2001/XMLSchema#string

Brett Glotzbecker

http://www.w3.org/2001/XMLSchema#string

Corey Cutler

http://www.w3.org/2001/XMLSchema#string

Edwin P Alyea

http://www.w3.org/2001/XMLSchema#string

Erin Coughlin

http://www.w3.org/2001/XMLSchema#string

Haesook T Kim

http://www.w3.org/2001/XMLSchema#string

John Koreth

http://www.w3.org/2001/XMLSchema#string

Joseph H Antin

http://www.w3.org/2001/XMLSchema#string

Karen K Ballen

http://www.w3.org/2001/XMLSchema#string

P304

1374-1380

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2013.06.008

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

241691925

http://www.w3.org/2001/XMLSchema#string

P698

23791626

http://www.w3.org/2001/XMLSchema#string